The DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.
The Metabolic Profile of Tumors Depends on Both the Responsible Genetic Lesion and Tissue Type
Open accessAbstract
The altered metabolism of tumors has been considered a target for anticancer therapy. However, the relationship between distinct tumor-initiating lesions and anomalies of tumor metabolism in vivo has not been addressed. We report that MYC-induced mouse liver tumors significantly increase both glucose and glutamine catabolism, whereas MET-induced liver tumors use glucose to produce glutamine. Increased glutamine catabolism in MYC-induced liver tumors is associated with decreased levels of glutamine synthetase (Glul) and the switch from Gls2 to Gls1 glutaminase. In contrast to liver tumors, MYC-induced lung tumors display increased expression of both Glul and Gls1 and accumulate glutamine. We also show that inhibition of Gls1 kills cells that overexpress MYC and catabolize glutamine. Our results suggest that the metabolic profiles of tumors are likely to depend on both the genotype and tissue of origin and have implications regarding the design of therapies targeting tumor metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, inhibiting glutamine entry into the TCA cycle can blunt tumor progression in a MYC-driven cancer model of liver cancer (Xiang et al., 2015; Yuneva et al., 2012) and a MYC-inducible Burkitt lymphoma model (Le et al., 2012; Xiang et al., 2015).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Yuneva et al., 2012
In the citing paper
“MYC has been found to increase mRNA and protein levels of glutamine transporters as well as expression of the enzyme glutaminase, which catalyzes the first step in glutaminolysis (Gao et al., 2009; Wise et al., 2008; Yuneva et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Yuneva et al., 2012
In the citing paper
“Second, although different oncogenes reprogram metabolism in different ways, the tissue in which the oncogene is expressed affects the execution of metabolic reprogramming.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [5]
In the citing paper
“Transgenic MYC induces metabolic changes in both liver tumors and lung tumors but activates glutamine catabolism in lung tumors and glutamine synthesis in liver tumors.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [5]
In the citing paper
“MYC-driven cancer cells exhibit enhanced glutamine utilization accompanied by increased expression of key glutaminolysis enzymes, including GLS1/GLS2 and GLUD1178–180.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [179]
In the citing paper
“For example, liver tumors with aberrant overexpression of MYC display enhanced glutamine oxidation and sensitivity to therapies that target glutamine catabolism relative to liver tumors driven by overexpression of MET (196).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [196]
In the citing paper
“furthermore, a similar accumulation of glucose-derived glutamine within the tumor tissue was observed in a mouse model of c-Met-driven liver cancer (Yuneva et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Yuneva et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,346
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy
Nicklin, P., Bergman, P., Zhang, B., Triantafellow, E., Wang, H., Nyfeler, B., Yang, H., Hild, M., Kung, C., Wilson, C., et al. (2009) · Cell · doi:10.1016/j.cell.2008.11.044 · Cited by 1,798
Wnt signalling and its impact on development and cancer
Klaus, A., & Birchmeier, W. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2389 · Cited by 1,595
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575
Molecular pathogenesis of human hepatocellular carcinoma
Thorgeirsson, S. S., & Grisham, J. W. (2002) · Nature Genetics · doi:10.1038/ng0802-339 · Cited by 1,456
Cited by
Sorted by citations
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
Metabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740
Understanding the Intersections between Metabolism and Cancer Biology
Heiden, M. G. V., & DeBerardinis, R. J. (2017) · Cell · doi:10.1016/j.cell.2016.12.039 · Cited by 2,369
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
Metadata
- Authors
- Yuneva, M. O., Fan, T. W. M., Allen, T. D., Higashi, R. M., Ferraris, D. V., Tsukamoto, T., Matés, J. M., Alonso, F. J., Wang, C., Seo, Y., Chen, X., & Bishop, J. M.
- Affiliations
- University of California, San Francisco (US)
- University of Louisville (US)
- Johns Hopkins University (US)
- Universidad de Málaga (ES)
- Corresponding author
- Yuneva, Mariia O.
- ORCID
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 15
- Issue
- 2
- Pages
- 157-170
- ISSN
- 1550-4131 (ISSN-L)
- PMC
- PMC3282107
- OpenAlex
- W2036659083
- Cited by
- 639
- References
- 64
- Citations by year
- 2026: 17 · 2025: 37 · 2024: 35 · 2023: 41 · 2022: 53 · 2021: 66 · 2020: 43 · 2019: 59 · 2018: 45 · 2017: 63 · 2016: 47 · 2015: 39 · 2014: 42 · 2013: 34 · 2012: 16
- FWCI
- 13.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R35CA044338, R01CA118434)
- National Institute of Neurological Disorders and Stroke (R21NS074151)
- National Center for Research Resources (P20RR018733)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- cancer metabolism, c-Myc, MET, glutamine catabolism, glutamine synthetase, glutaminase, GLS1, GLS2, liver tumors, lung cancer, genetic lesions, glutamine accumulation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Citric Acid Cycle, Glucokinase, Glucose, Glutamine, Humans, Immunohistochemistry, Isotope Labeling, Liver Neoplasms, Experimental, Lung Neoplasms, Immunoblotting, Blotting, Western, Proto-Oncogene Proteins c-myc, DNA Primers, Lactic Acid, Proto-Oncogene Proteins c-met, Nuclear Magnetic Resonance, Biomolecular, RNA Interference, Cell Line, Tumor, Mice, Metabolome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
